Harmony Biosciences
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 29 in the most recent period (2026/Q3).
- Total institutional ownership rose 6.3 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 114.31% +6.25pp
- Institutions
- 421 +29
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 24 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| Marshman Fund Trust II | -- | 10.30% |
| Sandip Kapadia | Former Chief Financial Officer | 0.04% |
| Kumar Budur | Executive VP and Chief Medical & Scientific Officer | 0.02% |
| Jeffrey Dayno | Chief Executive Officer | 0.02% |
| Andrew Serafin | Chief Strategy Officer | 0.01% |
| Adam Zaeske | Executive Vice President | 0.01% |
| Stephen Mollichella | Senior VP, Controller & Interim Principal Financial Officer | 0.00% |
| Jeffrey Aronin | Non-Executive Chairperson | 0.00% |
| R. Graf | Independent Director | -- |
| Gary Sender | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-17 | Kumar Budur | Executive VP and Chief Medical & Scientific Officer | Derivative Exercise and Sale | -38,452 | $30.27–43.05 |
| 2026-09-17 | Kumar Budur | Executive VP and Chief Medical & Scientific Officer | Intent to Sell (Form 144) | -35,852 | $42.74 |
| 2026-09-16 | Kumar Budur | Executive VP and Chief Medical & Scientific Officer | Intent to Sell (Form 144) | -800 | $42.21 |
| 2026-09-15 | Kumar Budur | Executive VP and Chief Medical & Scientific Officer | Intent to Sell (Form 144) | -1,800 | $42.17 |
| 2026-09-07 | Kumar Budur | Executive VP and Chief Medical & Scientific Officer | Automatic Disposition | -11,000 | $41.98–42.79 |
| 2026-09-07 | Kumar Budur | Executive VP and Chief Medical & Scientific Officer | Derivative Exercise and Sale | -22,954 | $30.27–43.10 |
| 2026-09-03 | Kumar Budur | Executive VP and Chief Medical & Scientific Officer | Intent to Sell (Form 144) | -5,500 | $41.86 |
| 2026-08-06 | Valor Management LLC | -- | Intent to Sell (Form 144) | -700,883 | $37.90 |
| 2026-07-15 | Stephen Mollichella | Senior VP, Controller & Interim Principal Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-07-01 | Sandip Kapadia | Former Chief Financial Officer | Intent to Sell (Form 144) | -25,000 | $36.96 |
| 2026-06-29 | Sandip Kapadia | Former Chief Financial Officer | Intent to Sell (Form 144) | -50,000 | $36.08 |
| 2026-06-25 | Sandip Kapadia | Former Chief Financial Officer | Intent to Sell (Form 144) | -45,594 | $35.24 |
| 2026-06-23 | Sandip Kapadia | Former Chief Financial Officer | Intent to Sell (Form 144) | -4,406 | $35.02 |
| 2026-06-08 | Sandip Kapadia | Former Chief Financial Officer | Intent to Sell (Form 144) | -27,960 | $33.74 |
| 2026-06-04 | Sandip Kapadia | Former Chief Financial Officer | Intent to Sell (Form 144) | -2,101 | $33.08 |
| 2026-06-03 | Sandip Kapadia | Former Chief Financial Officer | Intent to Sell (Form 144) | -7,064 | $33.02 |
| 2026-05-13 | R. Graf | Independent Director | Other Derivative Acquisition | +21,872 | $30.76 |
| 2026-05-13 | Gary Sender | Independent Director | Other Derivative Acquisition | +21,872 | $30.76 |
| 2026-05-13 | Linda Szyper | Independent Director | Other Derivative Acquisition | +21,872 | $30.76 |
| 2026-05-13 | Geno Germano | Independent Director | Other Derivative Acquisition | +21,231 | $30.76 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.
Harmony Biosciences discussion 0 comments